MERSANA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.57 USD | -1.53% |
|
-24.41% | +10.78% |
| May. 09 | Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M | MT |
Presenter SpeechUnknown Analyst (Analysts)Hello, everyone. Apologies for the late delay here. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Calendar
2024-06-11
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.61
USD
Average target price
6.375
USD
Spread / Average Target
+144.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.78% | 319M | |
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
- Stock Market
- Equities
- MRSN Stock
- News Mersana Therapeutics, Inc.
- Transcript : Mersana Therapeutics, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 04